Sai-Qi Wang
Overview
Explore the profile of Sai-Qi Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ren Y, Gong Y, Zhao H, You D, Li Z, Wang S, et al.
Chin J Cancer Res
. 2025 Jan;
36(6):669-682.
PMID: 39802899
Gastric cancer (GC) ranks 3rd in incidence rate and mortality rate among malignant tumors in China, and the age-standardized five-year net survival rate of patients with GC was 35.9% from...
2.
Zhu H, Zhou H, Zhou X, Li S, Zheng M, Xu Z, et al.
J Med Chem
. 2024 Nov;
67(22):20172-20202.
PMID: 39540222
The dual inhibition of histone lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) has emerged as a promising strategy for cancer therapy. In this study, we report the discovery of...
3.
Wang S, Wang S, Chen X, Xu Q, Deng H, Teng Q, et al.
J Med Chem
. 2024 Oct;
67(21):18764-18780.
PMID: 39425773
Targeting ABCB1 is a promising strategy in combating multidrug resistance. Our cell-based phenotypic screening led to the discovery of novel triazolo[1,5-]pyrimidone-based ABCB1 modulators. Notably, was identified as a significant contributor...
4.
Wang B, Wang S, Zhou Y, Wang S, Gao Y, Liu H, et al.
J Med Chem
. 2024 Sep;
67(18):16165-16184.
PMID: 39264726
LSD1 (histone lysine-specific demethylase 1) has been gradually disclosed to act as an immunomodulator to enhance antitumor immune response. Despite the identification of numerous potent LSD1 inhibitors, there remains a...
5.
Hu H, Wang S, Shang H, Lv H, Chen B, Gao S, et al.
Front Pharmacol
. 2024 Feb;
15:1274209.
PMID: 38410129
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that exhibits high expression in various tumors and is associated with a poor prognosis. FAK activation promotes tumor growth, invasion, metastasis,...
6.
Hu H, Wang S, Zhao H, Chen Z, Shi X, Chen X
Int J Oncol
. 2024 Feb;
64(4).
PMID: 38391024
Human epidermal growth factor receptor 2 (HER2) gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2...
7.
Dai X, Ji S, Fu M, Liu G, Liu H, Wang S, et al.
Theranostics
. 2024 Feb;
14(4):1464-1499.
PMID: 38389844
Epigenetics refers to the reversible process through which changes in gene expression occur without changing the nucleotide sequence of DNA. The process is currently gaining prominence as a pivotal objective...
8.
Zhang J, Wang Y, Sun L, Wang S, Chen Z
Mol Biomed
. 2023 Sep;
4(1):26.
PMID: 37661221
The pharmaceutical industry had a glorious year in 2022, with a total of 37 new drugs including 20 new chemical entities (NCEs) and 17 new biological entities (NBEs) approved by...
9.
Bai Y, Yang W, Hou X, Shen D, Zhang S, Li Y, et al.
Eur J Med Chem
. 2023 Jul;
258:115606.
PMID: 37402343
The interleukin-1 receptor associated kinase 4 (IRAK-4) is a member of serine-threonine kinase family, which plays an important role in the regulation of interleukin-1 receptors (IL-1R) and Toll-like receptors (TLRs)...
10.
Yuan S, Shen D, Bai Y, Zhang M, Zhou T, Sun C, et al.
Eur J Med Chem
. 2023 Mar;
250:115239.
PMID: 36893700
Due to the long-term and widespread use of antibiotics in clinic, the problem of bacterial resistance is increasingly serious, and the development of new drugs to treat drug-resistant bacteria has...